Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03496974 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT03496974: Completed Phase 2 study, sponsored by Janssen Research & Development.
NCT03496974 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03496974, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
Primary Outcome
Safety and tolerability endpoints were evaluated by monitoring all the adverse events from clinical and laboratory reporting, vital signs, physical examinations, ECG and urinalysis. All the Adverse Events that the subjects experienced from Visit 1 Day 1 (Post-injection) until 7 days after the last administration of the study drug were captured in the clinical database. AEs are coded using medical dictionary - MedDRA Version 21.0 and the severity was assigned using CTCAE version 4.03.
Interventions
- DRUG Bermekimab Monoclonal Antibody 400 mg
- DRUG Bermekimab Monoclonal Antibody 200 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2018-12-11 |
| Phase | Phase 2 |
What the finished NCT03496974 record still lists
NCT03496974 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Bermekimab Monoclonal Antibody 400 mg is the first listed.
NCT03496974 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03496974 about?
NCT03496974 is a clinical study titled "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis". A Phase 2 study of Bermekimab (MABp1) in patients with atopic dermatitis.
What is the current status of trial NCT03496974?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2018-05-21. Estimated completion is 2018-12-11.
What interventions are being tested in trial NCT03496974?
The interventions under investigation include: Bermekimab Monoclonal Antibody 400 mg (DRUG), Bermekimab Monoclonal Antibody 200 mg (DRUG).
Who is sponsoring clinical trial NCT03496974?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03496974's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI